NCT01246622View on ClinicalTrials.gov

Lenalidomide and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 7, 2011

Primary Completion Date

May 15, 2014

Study Completion Date

June 5, 2019

Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Recurrent Adult Acute Myeloid Leukemia
Interventions
DRUG

cytarabine

Given IV

DRUG

lenalidomide

Given PO

Trial Locations (1)

14263

Roswell Park Cancer Institute, Buffalo

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Roswell Park Cancer Institute

OTHER